anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We will first test a biopsy of the tumor (that has already been done) to see if your tumor cells are EBV positive. If the patient is eligible, we will then take 60-70 ml (12-14 teaspoons) of blood from them. We will use this blood to grow more of the T cells in the laboratory. We will first grow an EBV-infected cell line by infecting the blood with EBV virus. This line will then be irradiated so it cannot grow and used to stimulate the T cells. This stimulation will train the T cells to kill cells with EBV on their surface. We will then grow these EBV-specific CTLs by more stimulation with EBV infected cells and a growth factor called Interleukin 2. Next, we will test the T cells to make sure that they kill the EBV-infected cells. If the number of T cells produced is low, we may need to obtain additional blood samples to make these cells.

The cells (which are the patient's own T cells) will be injected into them over 10 minutes, after pretreatment with Tylenol and Benadryl. A total of two doses will be given two weeks apart. All of the Treatments will be given by the Center for Cell and Gene Therapy at Texas Children's Hospital or the Methodist Hospital.

We will follow the patient in the clinic after the injections. To learn more about the way the T cells are working and how long they last in the body, an extra 10-60 mls (2-12 teaspoons) of blood will be taken before the infusion and 3-4 days after the infusion (this is optional). Up to 40 ml (8 teaspoons) of blood will also be drawn at 1, 2, 4 and 6 weeks post-infusion, and then at 3, 6, 9, and 12 months. The blood may be drawn from the patient's central line at the time of the regular blood tests. We will use this blood to look at the immune response to the patient's cancer. Over the course of the study, up to 29 tablespoons of blood will be drawn.

Patients will also have repeat scans at 8 weeks after the first injections. If these show stable or improving disease they may (if the patient wishs) receive up to 6 extra doses of cells. These would be given every 1-3 months. If the patient has additional injections of cells after the first two infusions, we will take extra blood tests before each infusion, at the end of each infusion, 3-4 days after each infusion (day optional depending on patient preference), and at 1 and 2 weeks after each infusion. We will also do an extra scan between 1 and 3 months after the last infusion. Follow up will then continue every 3 months and will continue until 12 months after the last infusion.
The present invention relates to C. elegans insulin-like genes and methods for identifying insulin-like genes. The methods provide nucleotide sequences of C. elegans insuline-like genes, amino acid sequences of their encoded proteins, and derivatives (e.g., fragments) and analogs thereof. The invention further relates to fragments (and derivatives and analogs thereof) of insuline-like proteins which comprise one or more domains of an insulin-like protein. Antibodies to an insuline-like protein, and derivatives and analogs thereof, are provided. Methods of production of an insuline-like protein (e.g., by recombinant means), and derivatives and analogs thereof, are provided. Further, methods to identify the biological function of a C. elegans insulin-like gene are provided, including various methods for the functional modification (e.g., overexpression, underexpression, mutation, knock-out) of one or more genes silmutaneously. Still further, methods to identify a C. elegans gene which modifies the function of, and/or functions in a downstream pathway from, an insulin-like gene are provided.
PROBLEM TO BE SOLVED: To obtain the subject alkaline composition capable of simply and readily shaving moustache, scarcely becoming itchy by shaving and imparting moistness to skin after the shaving by including a thermal base. SOLUTION: This composition is obtained by including a thermal base capable of making a sense of warmth felt when applied to skin (e.g. a humectant, an a inorganic salt and a blood circulation promoter, preferably the humectant such as glycerol or dipropylene glycol) and regulating the composition to an alkaline state (preferably pH 8-11). The viscosity of the composition is preferably 5,000-30,000 mPa.s/30 deg.C. When a humectant is used as the thermal base, the amount thereof formulated is preferably >=80 wt.%. The regulation of the pH is carried out by formulating caustic soda, caustic potash, triethanolamine, etc. Water in an amount of 0.5-25.0 wt.% is preferably further formulated in the composition.
TOLSURA can cause or exacerbate congestive heart failure (CHF) [see Boxed Warning and Adverse Reactions (6.1)]. For patients with evidence of ventricular dysfunction such as CHF, history or risk factors for CHF, physicians should carefully review the risks and benefits of TOLSURA therapy. These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders. Inform such patients of the signs and symptoms of CHF and monitor carefully for signs and symptoms of CHF during treatment. If signs or symptoms of CHF appear or worsen during administration of TOLSURA, reassess the benefit-risk of continuing treatment.

When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was demonstrated. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later.

Itraconazole has been associated with reports of CHF, peripheral edema, and pulmonary edema. In post-marketing experience, heart failure was more frequently reported in patients receiving higher total daily doses of itraconazole of 400 mg although there were also cases reported among those receiving lower total daily doses [see Adverse Reactions (6.2)].

Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, when co-administering itraconazole and calcium channel blockers, monitor carefully for signs and symptoms of CHF during treatment due to an increased risk of CHF. Concomitant administration of TOLSURA and felodipine or nisoldipine is contraindicated [see Contraindications (4.1), Drug Interactions (7.1) and Adverse Reactions (6.2)]
In this randomized design, study participants (n=30) will take a supplement 3 times per day for 14 days and will be followed throughout completion of the concussion protocol, up to one year. The initial visit (pre-experimental visit) will serve to obtain informed consent, anthropometric information, a 24-hour dietary recall, health and lifestyle questionnaire, and circulating metabolites. Randomization will also occur at the initial visit and will be done by a computer to determine each participant's group assignment. Unless otherwise specified, follow up visits (experimental visits) will involve an identical clinical protocol as described below. The following are clinical tests that will be conducted during study visits:

Initial Visit: Participants will arrive to the Concussion Clinic in the Sports Medicine Clinic at Children's of Alabama for their routine initial visit. Participants will be provided with the study protocol, the purpose of the study, and routine and potential risks associated with the study procedures. Participants will then fill out the informed consent/assent, health and lifestyle questionnaire, and 24-hour dietary recall. As part of standard of care, height and weight will be measured using a stadiometer, body mass index (BMI) will be calculated, circulating metabolites will be collected, and resting blood pressure will be measured using a standard blood pressure cuff and a stethoscope. The SCAT5 will be conducted by a licensed healthcare professional. For research-specific purposes, body composition will be measured using BIA, C3Logix evaluation will be conducted by trained research personnel, and MRI scans will be taken. Participants will then be randomly assigned to 1 of 2 experimental groups and the appropriate supplement will be provided. Participants will also be provided with information regarding Return-to-Play progression and documents to track Return-to-Learn, supplement compliance, and GI distress.

Follow-up Visits: Participants will arrive to the Concussion Clinic in the Sports Medicine Clinic at Children's of Alabama for their routine follow up visits. Participants will fill out the 24-hour dietary recall. As part of standard of care, height and weight will be measured using a stadiometer, body mass index (BMI) will be calculated, circulating metabolites will be collected, and resting blood pressure will be measured using a standard blood pressure cuff and a stethoscope. The SCAT5 will be conducted by a licensed healthcare professional. For research-specific purposes, body composition will be measured using BIA and C3Logix evaluation will be conducted by trained research personnel. Data collection sheets for the Return-to-Learn Progression, supplement compliance, and GI distress will be collected. If applicable, data collection sheets for the Return-to-Play Progression will be collection. Supplement compliance and GI distress will only be collected at follow up visit #1. Return-to-Learn Progression will be evaluated at each visit until completion of the Return-to-Learn Protocol.
Stable infant will be nursed in a cardboard cot, lined with reflective film for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Incubator Care), and back for a total of 2 24-hour periods in each arm.
PURPOSE:To provide a Maillard reaction inhibitor containing a quinoline derivative and useful for the remedy and prevention of diseases caused by the complication of diabetes and aging. CONSTITUTION:The objective agent can be prepared by mixing a compound of formula [X is hydroxyl, =O, =N-R3 (R3 is bond on adjacent C atoms on the same 6-membered aromatic ring which may have hydroxyl group), etc.; Z is hydroxyl when X is hydroxyl and Z is =O other wise; W is H or hydroxyl; dotted line is conjugated double bond; R1 and R2 are H, lower alkyl, lower alkenyl, amino, etc.] or its salt with a pharmacologically allowable additive and forming in the form of medicine by conventional process. It can be used as tablet, pill, powder, granule, capsule, injection, eye drops, eye ointment, etc. Daily dose of the compound of formula is 1-100mg for oral administration and 0.1-100mg for injection and the concentration of the compound is 0.05-5W/V% for eye drops.
Participants complete 2 communication workshops about conversational skills and development of a video about the summer student's research experience over 3 hours each during the second week of the summer research experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
This is a multicenter, randomized, double-blind, placebo controlled study to evaluate the effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC) BID on arterial stiffness in COPD subjects. Following a 1 to 14 day run-in period, approximately 250 subjects will be randomly assigned to double-blind treatment for 12 weeks. After the 12 week treatment period, subjects in both treatment arms will receive open label Tiotropium bromide Handihaler18mcg (Tio)QD for 4 weeks in addition to their continued study drug (either FSC250/50 or placebo). The primary measure of efficacy is Pulse Wave Velocity (PWV) at Endpoint. Secondary efficacy measures include Augmentation Index (AIx), Biomarkers of cardiovascular disease, measures of lung function. (e.g. FEV1). Safety will be assessed through the collection of adverse events and COPD exacerbations. Exploratory endpoints include the effect of Tiotropium on PWV and AIx when added to placebo or FSC. Treatment groups will be stratified based on current smoking status. There will be a total of 6 study visits (screening, randomization, and after 4, 8, 12 and 16 weeks of treatment). A follow-up phone contact for collection of adverse event and pregnancy information (if applicable) will be conducted approximately 14 days following the last study visit.
Provided are compounds that generate a peroxide when they react with ozone in the presence of water. Additionally, alkyne compounds reactive with a free radical, a reactive oxygen species (ROS) or another reactive species are provided. Also provided are enol ether, enamine, and vinal thioester compounds reactive with a free radical, a strong acid, a reactive oxygen species (ROS) or another reactive species. Additionally provided are compounds reactive with a free radical, an ROS or another reactive species. The compounds comprise a conjugated moiety operably joined to an alkene moiety and a resonance-transmitting moiety, wherein the resonance-transmitting moiety transmits an electron through the conjugated moiety to the alkene moiety, which reacts with the free radical, an ROS or another reactive species. Also provided are methods of decomposing a free radical, an ROS or another reactive species. The methods comprise contacting the free radical or ROS with any of the above compounds. Also provided are methods of using any of the compounds described herein, and compositions comprising those compounds. Additionally provided are methods of producing the above compounds.
Each patient who is admitted for preoperative preparation for elective open heart surgery at Intermountain Medical Center will be invited to participate in this study. The patient's history and medical records will be reviewed and data gathered will be used to evaluate the patient's relationship to inclusion and exclusion criteria. After a written informed consent is obtained, subjects will be randomized 1:1 to the treatment arm or placebo/control arm. Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on the mornings of post-op days 1 and 2. Approximately 15-20 ml (about one tablespoon) of blood will be obtained at the following time periods (+/- 4 hours): 1) At baseline pre-procedure 12 to 18 hours before planned surgery; 2) Post-operative day 1, 12 to 24 hours after surgery; 3) 48 hours after surgery; 4) 72 hours after surgery; 5) At discharge (estimated to be between 5-8 days after surgery); and 6) At the 6-month follow-up visit (post-surgery). Each blood sample will be transported to The Center for Molecular and Genetic Research at LDS Hospital Cardiovascular Genetics Laboratory for preparation and storage. Plasma levels of 25(OH) vitamin D will be measured on each sample.
PURPOSE:A new antibiotic substance SF-2197A and to isolate and collect the pure substance SF-2197A from a culture, by cultivating a microorganism, belonging to the genus Microbispora, and capable of producing the substance SF- 2197A to give the culture. CONSTITUTION:A strain of SF-2197A is cultivated in a culture medium containing a carbon source, nitrogen source and if necessary othe inorganic salts added thereto utilizable by ordinary microorganisms. The liquid cultivation under aerobic conditions, particularly submerged cultivation method in the same manner as the well-known production of general antibiotic substances is most suited to the cultivation method. The temperature suitable for the cultivation is 20-30 deg.C, and the SF-2179 substance is obtained in a highest accumulation usually in 2-7 days. The resultant substance SF-2197A is a novel and useful antibiotic substance having an antimicrobial activity against various Gram-positive and Gram- negative bacteria, and has the respective specific physico-chemical properties, e.g. elementary analyses, molecular weight, melting point, specific rotatory power, ultraviolet absorption spectrum, etc.
Vaccine-related myocarditis associated with the BNT162b2 vaccine is a rare complication, with a higher risk observed in male adolescents. However, the contribution of genetic factors to this condition remains uncertain. In this study, we conducted a comprehensive genetic association analysis in a cohort of 43 Hong Kong Chinese adolescents who were diagnosed with myocarditis shortly after receiving the BNT162b2 mRNA COVID-19 vaccine. A comparison of whole-genome sequencing data was performed between the confirmed myocarditis cases and a control group of 481 healthy individuals. To narrow down potential genomic regions of interest, we employed a novel clustering approach called ClusterAnalyzer, which prioritised 2,182 genomic regions overlapping with 1,499 genes for further investigation. Our pathway analysis revealed significant enrichment of these genes in functions related to cardiac conduction, ion channel activity, plasma membrane adhesion, and axonogenesis. These findings suggest a potential genetic predisposition in these specific functional areas that may contribute to the observed side effect of the vaccine. Nevertheless, further validation through larger-scale studies is imperative to confirm these findings. Given the increasing prominence of mRNA vaccines as a promising strategy for disease prevention and treatment, understanding the genetic factors associated with vaccine-related myocarditis assumes paramount importance. Our study provides valuable insights that significantly advance our understanding in this regard and serve as a valuable foundation for future research endeavours in this field.
BACKGROUND: We aim to determine the multiethnic patterns of the prevalence and associated factors of poor muscle health and its associated components in older Chinese, Malays, and Indian Asian adults.
METHODS: We included 2199 participants (mean age ± SD: 72.9 ± 8.3 years; 54.3% female) from the baseline assessment of the Population Health and Eye Disease Profile in Elderly Singaporeans (PIONEER; 2017-2022) cohort study. Poor muscle health was defined as the presence of either low muscle mass (DEXA), or low muscle strength (handgrip strength), or low physical performance (gait speed). Its components include poor muscle function (low muscle strength and/or low physical performance without low muscle mass), pre-sarcopenia (low muscle mass only), and any sarcopenia (low muscle mass with low muscle strength and/or low physical performance). Sociodemographic, clinical, and lifestyle factors were assessed using biochemistry, clinical tests, and validated questionnaires. Regression models were utilized to evaluate the independent risk factors of poor muscle health and its components.
RESULTS: The national census-adjusted prevalence of poor muscle health (88%) was similar across the three ethnic groups. However, Chinese individuals had higher prevalence of pre-sarcopenia and any sarcopenia, and a lower prevalence of poor muscle function compared with Indians or Malays. We observed ethnic differences in modifiable risk factors (low physical activity, diabetes, osteoporosis, and obesity) of poor muscle health and its components. Although obesity was protective of pre-sarcopenia (RRR = 0.19, 95% CI: 0.11, 0.36) and any sarcopenia (RRR = 0.29, 95% CI: 0.18, 0.47) in the overall population and across ethnic groups, it was associated with 1.7 times (95% CI: 1.07, 2.67) the likelihood of poor muscle function in the entire population.
CONCLUSIONS: Almost 90% of community dwelling Singaporean aged ≥60 years have poor muscle health across the three ethnic groups with ethnic disparities in modifiable risk factors, highlighting an urgent need for community-wide targeted interventions to promote muscle health.
PROBLEM TO BE SOLVED: To obtain a new DNA having a specific base sequence, inserted in a plasmid retained by E.coli DH5 α etc., and encoding a protein activating monocytic cells and useful e.g. for the therapy of leukemia, autoimmune disease, cancer or the like. SOLUTION: This new DNA is one of the following DNAs: a DNA having a base sequence of formula I or the like; a DNA encoding a protein having an amino acid sequence of formula II or the like and; a DNA inserted in a plasmid retained by E. coli DH5 α (pSR αhHSGL) (FERM P-17331) or E.coli DH5 α (pSR α mHSGL) (FERM P-17332). The new DNA encodes a protein activating monocytic cells and is used e.g. for the production of the protein HSGL helpful e.g. for the therapy of leukemia, autoimmune disease, allergic disease, cancer or the like. The above DNA is obtained by EST cloning in the case of the DNA encoding human HSGL.
The invention relates to the use of one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for preventing or treating infectious diseases caused by a hepatitis B virus that is resistant to nucleoside analogues or in the event that a hepatitis B virus, which is resistant to nucleoside analogues, is involved in the development or progression of infectious diseases. The invention also relates to the use of one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for producing a medicament used for preventing or treating infectious diseases caused by a hepatitis B virus that is resistant to nucleoside analogues or in the event that a hepatitis B virus, which is resistant to nucleoside analogues, is involved in the development or progression of infectious diseases. The invention additionally relates to the use of one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for inhibiting the propagation of a hepatitis B virus that is resistant to nucleoside analogues. The invention also refers to methods for preventing or treating infectious diseases in a mammal caused by a hepatitis B virus that is resistant to nucleoside analogues or in the event that a hepatitis B virus, which is resistant to nucleoside analogues, is involved in the development or progression of infectious diseases, whereby one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are administered to the mammal. The invention further refers to methods for inhibiting the propagation of a hepatitis B virus that is resistant to nucleoside analogues, whereby one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are brought into contact with the viruses. In a preferred embodiment of the invention, the nucleoside analogues are selected from the group comprised of lamivudine and famciclovir.
Photopolymerizable polymer composites based on dimethacrylate systems have been increasingly utilized as dental restorative materials. One of the biggest drawbacks of current dental resin systems is the volume shrinkage and shrinkage induced stresses that arise during the polymerization. Other major problems include incomplete double bond conversion and insufficient wear resistance. This invention involves the development of an entirely novel approach to the photopolymerization process that utilizes thiol-ene systems as low shrinkage and ultra-low shrinkage stress dental restorative materials. Compared with the traditional dimethacrylate dental resins, these novel photopolymerizations have demonstrated a dramatically decreased volume shrinkage, extremely rapid polymerization, abilities to photopolymerize ultrathick materials and achieve much higher conversion, lack of oxygen inhibition and ultra-low shrinkage stress due to low volume shrinkage and drastically delayed gel point conversion. These polymers have thus shown outstanding suitability as dental restorative materials.